Celltrion, Inc. 068270.KS KSC · Healthcare · South Korea
₩213,000.00 -0.93% -₩2,000.00
Summary
57 / 100 · Bulios Score
What speaks for it
- Out of every 100 KRW of revenue, 24 KRW is left as net profit.
- Revenue grew by 22% a year over the last 3 years.
- Analysts expect revenue to grow by 38% this fiscal year.
What to watch
- The share price is above the Bulios Fair Price.
- It missed profit estimates 5 times in the last 8 quarters.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 37.0 KRW for 1 KRW of yearly profit. Over the last five years it was 50.3 KRW on average.
Valuation in detailIs it growing?
Yes, fastRevenue (KRW)
Diluted EPS (KRW)
- Analyst estimate
Revenue grew by 18% a year over 5 years. Over the last 3 years it grew by 22% a year. For the next fiscal year analysts expect revenue to grow by 38%.
Growth in detailDoes it make money?
Very wellWhere 100 KRW of revenue goes
- Cost of sales 28 KRW
- Research and development 1.0 KRW
- Sales and administration 39 KRW
- Taxes and other 8.2 KRW
- Net profit 24 KRW
Net profit, industry median (Biotechnology) -9.2 KRW
Out of every 100 KRW of revenue, 24 KRW is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.33%
- Paid out of profit
- 12%
- Raised in a row
- 3 years
You receive ₩714.29 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail